Tirzepatide vs Retatrutide: Dual vs Triple Agonist Comparison

Tirzepatide and retatrutide represent successive generations of multi-receptor agonist peptides. Tirzepatide activates two receptors (GIP and GLP-1), while retatrutide activates three (GLP-1, GIP, and glucagon). The addition of glucagon receptor agonism in retatrutide introduces a thermogenic component — glucagon increases energy expenditure and hepatic fat oxidation — potentially producing greater metabolic effects in test subjects. Both are administered once weekly and follow dose titration protocols. For research purposes only.

Tirzepatide (Dual GIP/GLP-1): Activates GIP receptors (enhanced insulin sensitivity, lipid metabolism) and GLP-1 receptors (appetite suppression, delayed gastric emptying). The two pathways produce synergistic metabolic effects. Retatrutide (Triple GLP-1/GIP/Glucagon): Activates all three incretin-related receptors. The glucagon component adds direct thermogenesis (increased resting energy expenditure), enhanced hepatic lipid oxidation, and glycogenolysis. This triple mechanism addresses metabolism from three angles simultaneously in test subjects — appetite reduction, insulin sensitisation, and energy expenditure increase.

Tirzepatide (approved-product label): • 2.5 mg once weekly for 4 weeks, then 5 mg once weekly • Later 2.5 mg increases occur only after at least 4 weeks at the current dose and should reflect response and tolerability • Dose increases are not automatic Retatrutide (investigational phase 2 context): • The trial tested a fixed 1 mg arm and target-dose arms of 4 mg, 8 mg, or 12 mg • Target-dose groups started at 2 mg or 4 mg and escalated every 4 weeks for up to 12 weeks • Gastrointestinal adverse events were dose-related and were partially mitigated by a 2 mg rather than 4 mg starting dose • Retatrutide has no approved public dosing schedule These programmes are not interchangeable, and neither supports automatic week-to-week dose increases. Sources: https://pi.lilly.com/us/zepbound-uspi.pdf and https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Receptor targets: Tirzepatide = GIP + GLP-1 | Retatrutide = GLP-1 + GIP + Glucagon Regulatory status: Tirzepatide = approved for specified indications and presentations | Retatrutide = investigational Frequency studied: Both = once weekly Starting step: Tirzepatide = 2.5 mg for 4 weeks under its label | Retatrutide = fixed 1 mg arm or 2 mg/4 mg starts in phase 2 target-dose arms Escalation interval: Tirzepatide = after at least 4 weeks | Retatrutide phase 2 = every 4 weeks for up to 12 weeks Maximum: Tirzepatide = 15 mg labelled maximum | Retatrutide = 12 mg highest phase 2 target, not an approved maximum Half-life: Tirzepatide = ~5 days | Retatrutide = ~6 days

Choose tirzepatide when: The protocol requires a well-characterised dual agonist with completed Phase 3 data, the research focus is on GIP/GLP-1 synergy, or a more conservative approach is preferred for test subjects. Choose retatrutide when: The protocol investigates triple-receptor activation and thermogenic effects, maximum metabolic impact is the research objective, or the study examines glucagon's role in energy expenditure and hepatic fat reduction in test subjects. Retatrutide is the newer compound with less published safety data but potentially greater efficacy based on early-phase trial results. Both are available as lyophilized research peptides from Australian suppliers. For research purposes only.